Phibro Animal Health (NASDAQ:PAHC) CEO Sells $400,600.20 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 9,660 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $41.47, for a total value of $400,600.20. Following the transaction, the chief executive officer owned 22,320 shares in the company, valued at approximately $925,610.40. This represents a 30.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total transaction of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total value of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total transaction of $8,554.08.

Phibro Animal Health Stock Performance

PAHC stock traded up $9.00 during mid-day trading on Thursday, reaching $50.00. The company had a trading volume of 981,708 shares, compared to its average volume of 238,086. The stock’s 50-day simple moving average is $39.88 and its two-hundred day simple moving average is $38.14. The stock has a market capitalization of $2.03 billion, a P/E ratio of 30.12, a P/E/G ratio of 1.17 and a beta of 0.80. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $50.05.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be given a $0.12 dividend. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 1.0%. Phibro Animal Health’s payout ratio is 28.92%.

Phibro Animal Health News Roundup

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Q2 results beat expectations — Phibro reported $0.87 EPS vs. consensus ~$0.69 and revenue of $373.9M vs. ~$355.6M, showing 21% year-over-year sales growth and a jump in net income. This beats drove the immediate market reaction. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Positive Sentiment: FY2026 guidance raised — management set full-year EPS guidance of $2.930–$3.100, above street consensus (about $2.75), and reiterated ~ $1.5B revenue guidance; the stronger EPS range is a primary bullish catalyst. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Positive Sentiment: Operational momentum highlighted — company disclosed improved margins, return on equity, and year-over-year net income growth (net income rose materially vs. prior year), supporting the upgraded guidance. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Neutral Sentiment: Full earnings materials published — the Q2 earnings call transcript and slide presentation are available for detailed read-throughs of segment trends, margin drivers and FX/commodity commentary (useful for assessing sustainability of the beat). Phibro Animal Health Corporation (PAHC) Q2 2026 Earnings Call Transcript Phibro Animal Health Corporation 2026 Q2 – Results – Earnings Call Presentation
• Neutral Sentiment: Dividend declared — board announced a $0.12 quarterly dividend (record/ex-dividend dates set), modestly supportive for income-focused holders but not a major catalyst.
• Negative Sentiment: Insider selling — filings show director Jack Bendheim sold multiple blocks of shares this reporting window; market interprets insider selling as a mild negative signal to weigh against the positive results. Jack Bendheim Sells 6,693 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock Jack Bendheim Sells 6,772 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock
• Negative Sentiment: Mixed/contradictory analyst and press coverage — some outlets flagged skepticism or pessimistic takes ahead/around the print, creating short-term volatility risk despite the beat; monitor follow-up analyst revisions. Zacks Research Has Pessimistic Outlook of PAHC Q2 Earnings

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Phibro Animal Health by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after buying an additional 546 shares during the last quarter. Millennium Management LLC boosted its holdings in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares during the period. Jane Street Group LLC grew its position in Phibro Animal Health by 65.3% in the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after purchasing an additional 13,404 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Phibro Animal Health by 7.6% during the 2nd quarter. State of Alaska Department of Revenue now owns 12,129 shares of the company’s stock worth $309,000 after purchasing an additional 859 shares during the period. Finally, Yousif Capital Management LLC acquired a new position in shares of Phibro Animal Health during the second quarter valued at about $200,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PAHC. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. JPMorgan Chase & Co. boosted their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.